Abstract

An adhesive composition including a calcium phosphate ceramic selected from tetracalcium phosphate and alpha-tricalcium phosphate, phosphorylated serine, polydopamine, and an aqueous solvent. Also, a kit for preparing the adhesive composition, which includes the calcium phosphate ceramic, phosphorylated serine, and polydopamine and a method for preparing the adhesive composition, as well as the uses thereof.

IPC Classes  ?

• A61L 24/00 - Surgical adhesives or cementsAdhesives for colostomy devices

Abstract

The present invention relates to antimicrobial peptides, variants and chemical analogues thereof; in particular, a peptide of 20 amino acids, named Michelicin, having the sequence RVCVRICRNGRCYRRCWNT, derived from a longer precursor with a BRICHOS domain from the marine worm Capitella. The peptide has several cysteines which form disulfide bridges and provide stability in salt conditions. Several derivatives and analogues were produced. The peptide and the derivatives show antimicrobial activity against a wide range of bacteria. The application also concerns nucleic acid sequences encoding these, pharmaceutical composition and to their use as a drug, preservative and disinfectant.

IPC Classes  ?

• C07K 14/435 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans
• A61K 38/00 - Medicinal preparations containing peptides
• A61P 31/04 - Antibacterial agents

Abstract

A radioactive seed loading and pushing device suitable for a brachytherapy treatment, the device including: a seed reservoir containing radioactive seeds, free with respect to one another; a flexible push cable and a motor-driven device for driving and guiding the push cable configured to make the push cable switch from a retracted position, clearing a loading area for a radioactive seed, up to a deployed position ensuring pushing of the seed; and a system ensuring loading of a seed from the reservoir up to the loading area.

IPC Classes  ?

• A61N 5/10 - X-ray therapyGamma-ray therapyParticle-irradiation therapy

Abstract

A fusion protein including fragments of the spike protein and of the nucleoprotein of a coronavirus. Also a vaccine, a composition, a pharmaceutical composition, or a diagnostic kit including the fusion protein, a method for diagnosing an infection by a coronavirus and to a method for preventing or treating a coronavirus infection based on the use of the fusion protein.

IPC Classes  ?

• A61K 39/215 - Coronaviridae, e.g. avian infectious bronchitis virus
• A61K 39/00 - Medicinal preparations containing antigens or antibodies
• A61P 37/04 - Immunostimulants
• C07K 14/005 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from viruses
• G01N 33/569 - ImmunoassayBiospecific binding assayMaterials therefor for microorganisms, e.g. protozoa, bacteria, viruses

Abstract

Device (1), for continuous-time energy calculation of an analog signal, comprising: a continuous-time analog-to-digital converter which is configured to convert the analog signal into a request signal (REQ), and a direction signal (DIR); at least one filtering unit (11), configured to output a filtered output signal (Fout), and comprising a delaying module (12) and a calculating module (15), connected to the delaying module (12) and configured calculate the filtered output signal (Fout). Device (1), for continuous-time energy calculation of an analog signal, comprising: a continuous-time analog-to-digital converter which is configured to convert the analog signal into a request signal (REQ), and a direction signal (DIR); at least one filtering unit (11), configured to output a filtered output signal (Fout), and comprising a delaying module (12) and a calculating module (15), connected to the delaying module (12) and configured calculate the filtered output signal (Fout). According to the invention, the device (1) further comprises: at least one pulse combiner (16), connected to the delaying module (12) and configured to output a combined request signal (CREQ); and at least one energy estimator (17), connected to the filtering unit (11) and to the pulse combiner (16), configured to compute a stored energy value (Aout) associated with each pulse of the combined request signal (CREQ).

IPC Classes  ?

• H03M 1/12 - Analogue/digital converters
• H03H 17/00 - Networks using digital techniques
• H03H 17/06 - Non-recursive filters
• H03M 1/06 - Continuously compensating for, or preventing, undesired influence of physical parameters

Abstract

“A signal, in particular radio-frequency signal, detector (10), such as a detector of wake-up radio type has a first circuit (20) receiving at its input the signal, configured to set the operating point (M) at the output to a predefined DC voltage (Vm_DC) to which a variable part (ΔVm) which is dependent on the signal from the input is added. A second circuit (30) is connected at its input to the output of the first circuit (20) and configured to amplify the variable part (ΔVm) of the signal, this second circuit has a chain of at least two logic inverters (32) in a cascade and operating below the threshold.

IPC Classes  ?

• H04B 1/16 - Circuits

Abstract

Devices and methods for conveying and controlling light beams, in particular for endomicroscopic imaging referred to as “lensless”. The devices and methods apply for example to endoscopic exploration, for example of organs of a living being even when the living being is able to move about freely during the measurement. More particularly, the devices and methods allow measurement of the transmission matrix of an optical fiber while “live”, even though the fiber may undergo changes in configuration.

IPC Classes  ?

• G01M 11/00 - Testing of optical apparatusTesting structures by optical methods not otherwise provided for

Abstract

The present invention concerns novel Gram-negative bacteria efflux pump inhibitors. It further relates to the use of Gram-negative bacteria efflux pump inhibitors to prevent and/or treat antibiotic resistance by potentiating the activity of antibiotics. Infections by multidrug resistant (MDR) Gram-negative bacteria are a major threat to global healthcare. The inventors have discovered a novel class of Resistance Nodulation cell Division-efflux pump inhibitors. The inventors tested the effects of these inhibitors on growth inhibition of different bacteria as well as their impact on the boosting of antibiotic activity in different bacteria. Particularly, the inventors tested the effects of these inhibitors on E. coli, A. baumamnii, K. pneumoniae and P. aeruginosa.

IPC Classes  ?

• C07D 213/74 - Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals
• A61K 31/4439 - Non-condensed pyridinesHydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
• A61K 31/4545 - Non-condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
• A61K 31/4709 - Non-condensed quinolines containing further heterocyclic rings
• A61K 31/495 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two nitrogen atoms as the only ring hetero atoms, e.g. piperazine
• A61K 31/496 - Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
• A61K 31/498 - Pyrazines or piperazines ortho- or peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
• A61K 31/55 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
• A61K 31/551 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogens as ring hetero atoms, e.g. clozapine, dilazep
• A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
• C07D 213/80 - AcidsEsters in position 3
• C07D 215/38 - Nitrogen atoms
• C07D 217/22 - Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the nitrogen-containing ring
• C07D 241/44 - Benzopyrazines with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the hetero ring
• C07D 295/073 - Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by halogen atoms or nitro radicals with the ring nitrogen atoms and the substituents separated by carbocyclic rings or by carbon chains interrupted by carbocyclic rings
• C07D 401/04 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring- member bond
• C07D 413/04 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring- member bond
• C07D 471/04 - Ortho-condensed systems
• C07D 471/08 - Bridged systems
• C07D 487/08 - Bridged systems

Abstract

A method of diagnosing an MSI cancer in a patient including extracting and sequencing DNA from a tumoral sample and if available from a normal sample and operate an analyse of MNRs. The method is based on the demonstration that the FDA-approved NGS-based diagnostic test for identifying MSI in mCRC and nmCRC gave inaccurate results when compared with the gold standard reference methods. Consequently, whole exome sequencing (WES) data from all samples was further analyzed to improve detection of the MSI genomic signal in CRC and other primary tumor types. This allowed identification of weaknesses and limits of MSISensor and the design and validation of a newly optimized algorithm, namely MSICare. The high accuracy of MSICare for the detection of MSI in CRC and non-CRC tumors should allow it to become a future reference test for assessing MSI in pan-cancer.

IPC Classes  ?

• C12Q 1/6886 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer

Abstract

The present invention arises from a formulation study in order to define the best excipients including buffer, surfactant, sugar and amino acid to stabilize Flagellin during mesh-nebulization. One of the key factors in stabilising proteins is determining the optimal pH and buffer system to provide adequate solubility and stability and avoid aggregate formation during the aerosolization process. Different formulation have been assayed in order to obtain a stable and soluble aerosol composition comprising flagellin polypeptide in particular considering the choice of the buffering agent, the surfactant and the pH of the liquid formulation comprising the flagellin polypeptide in order to maintain the activity of the flagellin after the aerosolization process. Accordingly, the present invention relates to an aerosol composition comprising droplets comprising a liquid formulation, wherein the liquid formulation comprises a flagellin polypeptide, a buffer (acetate and/or phosphate) and a surfactant (polysorbate). The aerosol composition of the present invention is suitable for the treatment of lung bacterial infections.

IPC Classes  ?

• A61K 38/16 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof
• A61K 9/00 - Medicinal preparations characterised by special physical form
• A61K 47/02 - Inorganic compounds
• A61K 47/12 - Carboxylic acidsSalts or anhydrides thereof
• A61K 47/26 - Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharidesDerivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin

Abstract

A compound of formula (I) or a pharmaceutically acceptable salt and/or hydrate thereof, for use in the treatment of a viral pulmonary disease or a chronic respiratory distress syndrome (CRDS) resulting from a viral pulmonary disease in a subject, the disease being different from COVID-19, wherein formula (I) is Z—R-A-R′—Y, including plerixafor.

IPC Classes  ?

• A61K 31/395 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
• A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
• A61P 31/16 - Antivirals for RNA viruses for influenza or rhinoviruses

Abstract

There is a need for novel therapies for the treatment of inflammation. Now, the inventors surprisingly show that clofoctol has potent anti-inflammatory properties. In particular, the inventors demonstrate that clofoctol treatment drastically reduced pulmonary inflammation in two models that recapitulate severe inflammation, one induced by the virus SARS-COV-2, and the other induced by LPS. Collectively, the data of the inventors justify to suggest that clofoctol would be suitable for the treatment of inflammation in general.

IPC Classes  ?

• A61K 31/05 - Phenols
• A61P 29/00 - Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agentsNon-steroidal antiinflammatory drugs [NSAID]

Abstract

A device for collecting a fraction of the perspiration excreted by a subject, the device being of the type including a multi-layer patch including: —a first layer including at least one perspiration-collecting aperture and a transfer opening; —a hydrophilic absorbent layer, positioned above the first layer and communicating with the external environment, and communicating with the first layer via the transfer opening; —a film, possibly transparent, that constitutes a barrier against water and against vapour, and that covers at least the upper face of the absorbent layer; the device notably including means for regulating the rate at which perspiration in the liquid and/or vapour state penetrates into the absorbent layer.

IPC Classes  ?

• A61B 10/00 - Instruments for taking body samples for diagnostic purposesOther methods or instruments for diagnosis, e.g. for vaccination diagnosis, sex determination or ovulation-period determinationThroat striking implements
• A61B 5/00 - Measuring for diagnostic purposes Identification of persons
• A61B 5/145 - Measuring characteristics of blood in vivo, e.g. gas concentration or pH-value
• A61B 5/1477 - Measuring characteristics of blood in vivo, e.g. gas concentration or pH-value using chemical or electrochemical methods, e.g. by polarographic means non-invasive
• A61F 13/534 - Absorbent pads, e.g. sanitary towels, swabs or tampons for external or internal application to the bodySupporting or fastening means thereforTampon applicators characterised by the absorbing medium having an inhomogeneous composition through the thickness of the pad
• A61F 13/537 - Absorbent pads, e.g. sanitary towels, swabs or tampons for external or internal application to the bodySupporting or fastening means thereforTampon applicators characterised by the absorbing medium having an inhomogeneous composition through the thickness of the pad characterised by a layer facilitating or inhibiting flow in one direction or plane, e.g. a wicking layer
• A61F 13/84 - Accessories, not otherwise provided for, for absorbent pads

Abstract

The invention relates to a device (5) comprising an optical surface (10) and a cleaning device (15) for cleaning the optical surface comprising:— a wave transducer (25) acoustically coupled with the optical surface and configured to synthesize an ultrasound wave (W) propagating within the optical surface, and— a spraying unit (20) for dispensing a washing liquid (L) onto the optical surface, the device being shaped so that the ultrasound wave displaces the washing liquid on the optical surface.

IPC Classes  ?

• B60S 1/52 - Arrangement of nozzles
• G02B 27/00 - Optical systems or apparatus not provided for by any of the groups ,

Abstract

The present disclosure relates to a composition for promoting plants growth and/or for protecting plants against at least one plant pest and/or one plant disease, the composition comprising simultaneously at least one bacteria of the genus Bacillus producing antifungal lipopeptides, at least one fungi of the genus Trichoderma, and at least one nitrogen mineral source. The present disclosure also relates to the use of such a composition and to a method for obtaining such a composition. The present disclosure also relates to a co-culture medium for producing at least in part such a composition.

IPC Classes  ?

• A01N 63/22 - Bacillus
• A01N 37/44 - Biocides, pest repellants or attractants, or plant growth regulators containing organic compounds containing a carbon atom having three bonds to hetero atoms with at the most two bonds to halogen, e.g. carboxylic acids containing at least one carboxylic group or a thio-analogue, or a derivative thereof, and a nitrogen atom attached to the same carbon skeleton by a single or double bond, this nitrogen atom not being a member of a derivative or of a thio-analogue of a carboxylic group, e.g. amino-carboxylic acids
• A01N 63/38 - Trichoderma
• A01P 1/00 - DisinfectantsAntimicrobial compounds or mixtures thereof
• A01P 3/00 - Fungicides
• A01P 5/00 - Nematocides
• A01P 7/04 - Insecticides
• A01P 15/00 - Biocides for specific purposes not provided for in groups
• A01P 21/00 - Plant growth regulators
• C05C 5/02 - Fertilisers containing other nitrates containing sodium or potassium nitrate

Abstract

A composition of yeast polysaccharides including β(1,6)-glucans, preferably also mannans and α-glucans. The yeast polysaccharides are extracted from yeast cell wall fragments. Typically, the β-glucans are β(1,6)-glucans. Also, a method for obtaining such a composition, including at least one step of fractionating a composition of yeast cell walls and extracting an insoluble fraction, and at least one step of extracting a soluble fraction from the insoluble fraction obtained in step a). Further, a composition with a human or veterinary therapeutic objective, for the treatment of gastrointestinal pathologies associated with pathogenic microorganisms, as well as to its non-therapeutic use for improving intestinal comfort.

IPC Classes  ?

• A61K 31/716 - Glucans
• A61K 36/064 - Saccharomycetales, e.g. baker's yeast
• A61P 31/04 - Antibacterial agents

Abstract

A method for controlling an electric microgrid comprising an electrical energy consuming element, an electrical energy production element and an electrical energy storage element, the method comprising the steps of extracting parameter values from a source model, the extraction phase being implemented by computer, initializing parameters of a target model with parameter values extracted from the source model, so as to obtain an initialized target model, the initialization phase being implemented by computer, and optimizing, according to a target domain and a target set of tasks, of the parameters of the initialized target model, so as to obtain a target model trained for the control of a target microgrid, the optimization phase being implemented by computer.

IPC Classes  ?

• H02J 3/32 - Arrangements for balancing the load in a network by storage of energy using batteries with converting means
• H02J 3/38 - Arrangements for parallelly feeding a single network by two or more generators, converters or transformers

Abstract

The use of CASD1 as a biomarker of a cancer expressing the O-acetylated-GD2 ganglioside. Also, a method of diagnosing a cancer expressing the O-acetylated-GD2 ganglioside, a method of selecting a subject suffering from a cancer expressing the O-acetylated-GD2 ganglioside for treatment targeting the cancer, or a method of monitoring the response of a subject suffering from a cancer expressing the O-acetylated-GD2 ganglioside to a treatment targeting the cancer.

IPC Classes  ?

• G01N 33/574 - ImmunoassayBiospecific binding assayMaterials therefor for cancer
• C12Q 1/6886 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer

Abstract

The present disclosure relates to novel compounds of formula (I) which are useful as inhibitors of endoplasmic reticulum aminopeptidases (ERAP), in particular as inhibitors of ERAP2. The disclosure also relates to the therapeutic use of these compounds, in particular the use of these compounds in the treatment or prophylaxis of proliferative disorders, autoinflammatory disorders and autoimmune disorders. The present disclosure relates to novel compounds of formula (I) which are useful as inhibitors of endoplasmic reticulum aminopeptidases (ERAP), in particular as inhibitors of ERAP2. The disclosure also relates to the therapeutic use of these compounds, in particular the use of these compounds in the treatment or prophylaxis of proliferative disorders, autoinflammatory disorders and autoimmune disorders.

IPC Classes  ?

• C07D 409/14 - Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
• A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
• C07D 409/12 - Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
• C07D 417/12 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group containing two hetero rings linked by a chain containing hetero atoms as chain links

Abstract

The invention relates to a device (5) comprising: —an optical surface (10); —a cleaning unit (15) for cleaning the optical surface, comprising at least one wave transducer (70) acoustically coupled to the optical surface, the wave transducer having a piezoelectric layer (80) and electrodes (85) of opposite polarity in contact with the piezoelectric layer, and being configured to generate at least one surface ultrasonic wave (WS) or a Lamb wave (WL) propagating in the optical surface; —the optical surface having at least one region of optical interest (100) not superposed on the wave transducer, the device comprising an apparatus (20) configured to sense and/or to emit radiation (R) through the region of optical interest (100).

IPC Classes  ?

• G02B 27/00 - Optical systems or apparatus not provided for by any of the groups ,
• B08B 7/02 - Cleaning by methods not provided for in a single other subclass or a single group in this subclass by distortion, beating, or vibration of the surface to be cleaned
• B60S 1/56 - Cleaning windscreens, windows, or optical devices specially adapted for cleaning other parts or devices than front windows or windscreens
• G01S 7/497 - Means for monitoring or calibrating

Abstract

Disclosed is a device (5) for cleaning an optical surface, which device comprises: —a transparent optical surface (10); —a cleaning unit (15) for cleaning the optical surface, having a piezoelectric layer (20) and at least two wave transducers (45), each wave transducer having electrodes (40) of opposite polarity in contact with the piezoelectric layer and being acoustically coupled to the optical surface so as to generate at least one surface ultrasonic wave (Ws) or a Lamb wave (WL) propagating in the optical surface, the transducers being further arranged on the periphery of the optical surface.

IPC Classes  ?

• B60S 1/56 - Cleaning windscreens, windows, or optical devices specially adapted for cleaning other parts or devices than front windows or windscreens
• B08B 7/02 - Cleaning by methods not provided for in a single other subclass or a single group in this subclass by distortion, beating, or vibration of the surface to be cleaned

Abstract

A method for the selective cleavage of a compound comprising an aromatic ring and a C—O—C linkage in the presence of a heterogeneous catalyst is provided. The heterogenous catalyst may be a supported noble metal catalyst doped with a halogen selected from the group consisting of chlorine and bromine. By using this method, it is possible to increase the selectivity and/or yield (preferably both) of aromatic compounds.

IPC Classes  ?

• C08H 7/00 - LigninModified ligninHigh-molecular-weight products derived therefrom
• B01J 23/46 - Ruthenium, rhodium, osmium or iridium
• B01J 21/18 - Carbon
• B01J 27/13 - Platinum group metals
• B01J 21/08 - Silica
• B01J 23/44 - Palladium
• C07C 37/54 - Preparation of compounds having hydroxy or O-metal groups bound to a carbon atom of a six-membered aromatic ring by reactions decreasing the number of carbon atoms by splitting polyaromatic compounds, e.g. polyphenolalkanes by hydrolysis of lignin or sulfite waste liquor
• C07C 1/22 - Preparation of hydrocarbons from one or more compounds, none of them being a hydrocarbon starting from organic compounds containing only oxygen atoms as hetero atoms by reduction

Abstract

The present invention relates to the pulsatile administration of the gonadotropin-releasing hormone (GnRH) for the treatment of food intake related disorder related disorder such as obesity (overeating) and anorexia (undereating). The inventors demonstrated that a population of mutant mice expressing BoNT/B in GnRH neurons (Gnrh::cre;iBot overweight), in which the GnRH release is inhibited, did not only fail to reach puberty onset and showed hypogonadotropic hypogonadism, but also developed overweight and hyperleptinemia. Unexpectedly, they found that the increase in body weight in mutant mice persisted in adulthood despite a significant decrease in food intake. Using a mouse model of obesity inventors observed an altered pattern of pulsatile LH secretion and that the frequency of LH pulses is inversely correlated to body weight and adiposity demonstrating that the heavier the animals were getting the more the GnRH/LH pulsatile pattern was altered. The present inventors further demonstrated that pulsatile GnRH treatment can allow to restore a control/lean pattern of GnRH/LH release in obese mice, and that this pulsatile administration of a “lean pattern” of native GnRH peptide in obese mice normalized their cumulative food intake to levels comparable with lean mice.

IPC Classes  ?

• A61K 38/09 - Luteinising hormone-releasing hormone [LHRH]Related peptides
• A61P 3/04 - AnorexiantsAntiobesity agents

Abstract

Disclosed is a device for detecting a pressure, of the type including a detection element on which a pressure is exerted, a transducer connected to the detection element and an elastically deformable shell. The shell is made of biocompatible and sterilizable material, has two opposing walls and an insertion opening, and the detection element includes at least one elastically deformable tube, the tube includes a portion arranged in the shell, the tube is closed at one end and filled with a fluid, the other end of the tube being open, arranged outside the shell and connected to the transducer.

IPC Classes  ?

• A61B 17/44 - Obstetrical forceps

Abstract

In the present invention, inventors provide compelling evidence showing that PCOS neuroendocrine reproductive and metabolic dysfunctions are transmitted in PAMH mice for at least three generations. Inventors employed genome-wide methylated DNA immunoprecipitation (MeDIP) analysis to characterize methylated genes in ovaries from control and PAMH mice of the third generation, the first unexposed transgenerational offspring, together with transcriptome analysis in these tissues. Inventors identified many genes with altered transcriptome expression in ovarian tissues of PCOS-animals and they show that several key molecules associated to the PCOS phenotype are epigenetically regulated through DNA hypomethylation. Inventors report that several differentially methylated signatures found in the ovaries of PCOS-like mice are also present in blood samples from women with PCOS and from daughters born to women with PCOS. Accordingly, the present invention relates to methods for diagnosis of the Polycystic Ovary Syndrome (PCOS) through detection of the methylation status of set of gene of the invention in a biological sample obtained from a subject or a patient. The present invention also relates to a method of preventing or treating a Polycystic Ovary Syndrome (PCOS) in a subject in need thereof.

IPC Classes  ?

• C12Q 1/6883 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material

Abstract

The invention relates to a manufacturing method for manufacturing a positive electrode layer based on a lithiated material suitable for three-dimensional batteries, or 3D batteries, so as to obtain a lithiated material on a substrate, the lithiated material comprising several thin layers, i.e. layers that have thicknesses between 1 nm and 1 μm, are made up of electrochemically active complex materials, and are, inter alia, homogeneous and suitable for conforming to the raised patterns of greater or lesser complexity of the surface of the substrate on which the lithiated material is deposited.

IPC Classes  ?

• C23C 16/455 - Chemical coating by decomposition of gaseous compounds, without leaving reaction products of surface material in the coating, i.e. chemical vapour deposition [CVD] processes characterised by the method of coating characterised by the method used for introducing gases into the reaction chamber or for modifying gas flows in the reaction chamber
• C23C 16/18 - Chemical coating by decomposition of gaseous compounds, without leaving reaction products of surface material in the coating, i.e. chemical vapour deposition [CVD] processes characterised by the deposition of metallic material from metallo-organic compounds
• C23C 8/12 - Oxidising using elemental oxygen or ozone

Abstract

In asthma, modification of gel-forming respiratory mucins leading to their tethering to the apical pole of epithelial cells, are believed to participate in airway obstruction by mucus plugs. These changes have been linked to local production of Th2 cytokines, resulting in mucus cell hyperplasia and increased MUC5AC production. The inventors showed that severe eosinophil asthma was associated with overexpression of transglutaminase 2 (TG2), an enzyme recently involved in intestinal mucin reticulation. Moreover, the bronchial epithelium from asthmatic patients or control subjects was reconstituted in vitro by culturing cells at the air-liquid interface and the hypersecretory differentiation was modeled by exposing control bronchial epithelial to IL-13. The inventors showed TG2 expression was upregulated upon IL-13-mediated hypersecretory differentiation and correlated with MUC5AC expression. IL-13 promoted MU5AC tethering to in vitro reconstituted hypersecretory epithelium, and this was blocked by a TG2 inhibitor. In conclusion, the inventors showed that TG2 participates in respiratory mucin modifications in asthma, and contribute to mucus tethering to the airway wall, supporting the use of TG2 inhibitors for improving mucociliary clearance in asthma, but more generally in respiratory diseases.

IPC Classes  ?

• A61K 38/07 - Tetrapeptides
• A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
• A61P 11/12 - Mucolytics

Abstract

The present invention relates to a bacterial strain of the species Parabacteroides distasonis for use thereof in the treatment and/or prevention of a gastrointestinal disease, or of a disorder associated with gastrointestinal disease, in an individual, said bacterial strain being selected from the group consisting of: the bacterial strain deposited with the CNCM under accession number CNCM I-5576; and the bacterial strain deposited with the CNCM under accession number CNCM I-5578. It further relates to a bacterial strain deposited with the CNCM under accession number CNCM I-5576 and to a bacterial strain deposited with the CNCM under accession number CNCM I-5578. The present invention finally relates to a composition comprising, in a physiologically acceptable medium, a least a bacterial strain of the invention.

IPC Classes  ?

• A61K 35/741 - Probiotics
• A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
• A61P 3/04 - AnorexiantsAntiobesity agents
• A61P 29/00 - Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agentsNon-steroidal antiinflammatory drugs [NSAID]
• A61P 1/00 - Drugs for disorders of the alimentary tract or the digestive system

IPC Classes  ?

• B01L 3/00 - Containers or dishes for laboratory use, e.g. laboratory glasswareDroppers

Abstract

Hepatitis E virus (HEV) is responsible for over 50% of acute viral hepatitis cases worldwide. The inventors have now identified the precise sequence of infectious particle-associated ORF2 capsid protein. Strikingly, their analyses revealed that in infected patients, HEV produces three forms of the ORF2 capsid protein: ORF2i, ORF2g and ORF2c. The ORF2i protein is associated with infectious particles whereas ORF2g and ORF2c proteins are massively produced glycoproteins that are not associated with infectious particles and are the major antigens present in HEV-infected patient sera. Accordingly, the ORF2i and ORF2g proteins are thus the subject matter of the present invention as well as antibodies specific for the proteins and diagnostic assays (e.g. ELISA) for the diagnosis of Hepatitis E virus infection.

IPC Classes  ?

• C07K 14/005 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from viruses
• C07K 16/10 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
• C12N 7/00 - Viruses, e.g. bacteriophagesCompositions thereofPreparation or purification thereof
• G01N 33/576 - ImmunoassayBiospecific binding assayMaterials therefor for hepatitis

Abstract

Electroacoustic device having a transducer including a piezoelectric substrate, first and second electrodes of inverse polarity having respective first and second tracks provided on said substrate, the first and second tracks spiraling around a same center (C), the transducer being configured for generating a swirling ultrasonic surface wave in the substrate.

IPC Classes  ?

• B01L 3/00 - Containers or dishes for laboratory use, e.g. laboratory glasswareDroppers
• G01N 15/1404 - Handling flow, e.g. hydrodynamic focusing
• G02B 21/32 - Micromanipulators structurally combined with microscopes
• H03H 9/145 - Driving means, e.g. electrodes, coils for networks using surface acoustic waves

Abstract

The present invention relates to a mixture of microorganisms comprising a Lactobacillus reuteri strain and a Lactobacillus salivarius strain, and to the use thereof for preparing an animal additive or feed product and for preventing or treating necrotic enteritis.

IPC Classes  ?

• A61K 35/747 - Lactobacilli, e.g. L. acidophilus or L. brevis
• A61P 1/00 - Drugs for disorders of the alimentary tract or the digestive system
• A61P 31/04 - Antibacterial agents
• C12N 1/20 - BacteriaCulture media therefor

Abstract

The disclosure relates to the use of clofoctol in the prevention or treatment of a disease caused by a coronavirus, in particular Covid-19.

IPC Classes  ?

• A61K 31/05 - Phenols
• A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
• A61P 31/14 - Antivirals for RNA viruses

Abstract

The present disclosure relates to modified forms, or muteins, of IL-10, as well as variants thereof, which display improved features as compared to wild-type IL-10. The present invention further relates to the use of such modified forms, or muteins, of IL-10, as well as variants thereof in methods, including therapeutic methods.

IPC Classes  ?

• C07K 14/54 - Interleukins [IL]
• A61P 37/02 - Immunomodulators

Abstract

A system and method for analyzing volatile organic compounds (VOCs) adsorbed on an adsorbent membrane, by low-temperature plasma and mass spectrometry (LTP-MS). The system includes a receptacle for receiving the adsorbent membrane, a low-temperature plasma ionizer configured to emit a plasma stream in a plasma emission direction, thereby ionizing the VOCs adsorbed by the membrane and forming a VOC-laden ionized gas, and a mass spectrometer for analyzing the ionized VOCs.

IPC Classes  ?

• H01J 49/04 - Arrangements for introducing or extracting samples to be analysed, e.g. vacuum locksArrangements for external adjustment of electron- or ion-optical components
• H01J 49/26 - Mass spectrometers or separator tubes
• G01N 33/497 - Physical analysis of biological material of gaseous biological material, e.g. breath
• H01J 49/10 - Ion sourcesIon guns

Abstract

The present invention relates to antimicrobial peptides, variants and chemical analogues thereof; in particular, a peptide of 20 amino acids, named Michelicin, having the sequence RVCVRICRNGRCYRRCWNT, derived from a longer precursor with a BRICHOS domain from the marine worm Capitella. The peptide has several cysteines which form disulfide bridges and provide stability in salt conditions. Several derivatives and analogues were produced. The peptide and the derivatives show antimicrobial activity against a wide range of bacteria. The application also concerns nucleic acid sequences encoding these, pharmaceutical composition and to their use as a drug, preservative and disinfectant.

IPC Classes  ?

• A61K 38/00 - Medicinal preparations containing peptides
• A61P 31/04 - Antibacterial agents
• C07K 14/435 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans

Abstract

The present invention relates to an adhesive composition comprising a calcium phosphate ceramic selected from tetracalcium phosphate and alpha-tricalcium phosphate, phosphorylated serine, polydopamine, and an aqueous solvent. The invention also relates to a kit, to a method for producing said adhesive composition as well as to the uses thereof.

IPC Classes  ?

• A61L 24/00 - Surgical adhesives or cementsAdhesives for colostomy devices

Abstract

A method of treating COVID-19 in a patient. The patient may be in moderate to advanced stages of COVID-19 infection. The method includes administering to the patient a therapeutically effective amount of at least one antagonist or inhibitor of chemokine receptor CXCR4. The at least one antagonist or inhibitor of chemokine receptor CXCR4 is distinct from hydroxychloroquine.

IPC Classes  ?

• A61K 31/395 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
• A61K 31/662 - Phosphorus acids or esters thereof having P—C bonds, e.g. foscarnet, trichlorfon
• A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
• A61P 31/14 - Antivirals for RNA viruses

Abstract

A protein capable of converting chlorogenic acid into isochlorogenic acid. The protein includes or is an amino acid sequence SEQ ID No. 1, a sequence having at least 80% identity with this sequence or a fragment of this sequence. Also, a process for producing isochlorogenic acid from chlorogenic acid, which includes producing the protein and bringing it into contact with chlorogenic acid.

IPC Classes  ?

• C12P 7/62 - Carboxylic acid esters
• C12N 9/18 - Carboxylic ester hydrolases
• C12N 15/81 - Vectors or expression systems specially adapted for eukaryotic hosts for fungi for yeasts
• C12N 15/82 - Vectors or expression systems specially adapted for eukaryotic hosts for plant cells

Abstract

The invention relates to antibodies against extracellular epitopes of human Transient Receptor Potential Vanilloid 6 (TRPV6) channel protein, in particular antibodies which modulate TRPV6 channel activity on the plasma membrane and thereby trigger apoptosis of cancer cells expressing TRPV6. The invention relates also to the use of said antibodies for the diagnosis, prognosis and treatment of diseases involving TRPV6 channels, in particular diseases associated with TRPV6-expression such as cancers. The invention further relates to peptide antigens from human TRPV6 protein useful for the production of said antibodies.

IPC Classes  ?

• A61K 39/395 - AntibodiesImmunoglobulinsImmune serum, e.g. antilymphocytic serum
• A61P 35/00 - Antineoplastic agents
• A61P 35/04 - Antineoplastic agents specific for metastasis
• C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
• C12N 15/113 - Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides
• G01N 33/53 - ImmunoassayBiospecific binding assayMaterials therefor

Abstract

The present invention relates to devices and methods for transporting and monitoring light beams, especially for so-called "lensless" endo-microscopic imaging. The present invention is for example applicable to endoscopic exploration, for example of organs of a living being whilst the latter is able to move freely during the measurement. More particularly, the present invention allows the transmission matrix of the fibre to be measured "directly", whilst the fibre potentially undergoes changes of configuration. The present invention also relates to a fibre-optic device suitable for implementing the method.

IPC Classes  ?

• G01M 11/00 - Testing of optical apparatusTesting structures by optical methods not otherwise provided for

Abstract

opt) of physical parameters minimizing said error function.

IPC Classes  ?

• G01N 21/3586 - Investigating relative effect of material at wavelengths characteristic of specific elements or molecules, e.g. atomic absorption spectrometry using infrared light using far infrared lightInvestigating relative effect of material at wavelengths characteristic of specific elements or molecules, e.g. atomic absorption spectrometry using infrared light using Terahertz radiation by Terahertz time domain spectroscopy [THz-TDS]
• G01N 21/3504 - Investigating relative effect of material at wavelengths characteristic of specific elements or molecules, e.g. atomic absorption spectrometry using infrared light for analysing gases, e.g. multi-gas analysis
• G01N 21/35 - Investigating relative effect of material at wavelengths characteristic of specific elements or molecules, e.g. atomic absorption spectrometry using infrared light

Abstract

The present invention relates to the use of a catalyst made of rhenium oxide supported by cerium oxide, with formula ReOx/CeO2 (I), for catalyzing the deoxydehydration of glycerol to allyl alcohol, the reaction being carried out under heterogeneous conditions in the presence of at least one aliphatic alcohol; and to a method for producing allyl alcohol from glycerol in the presence of the catalyst.

IPC Classes  ?

• B01J 23/36 - Rhenium
• C07C 29/60 - Preparation of compounds having hydroxy or O-metal groups bound to a carbon atom not belonging to a six-membered aromatic ring by elimination of hydroxy groups, e.g. by dehydration
• B01J 23/10 - Catalysts comprising metals or metal oxides or hydroxides, not provided for in group of rare earths
• B01J 35/10 - Solids characterised by their surface properties or porosity
• B01J 37/02 - Impregnation, coating or precipitation
• B01J 37/08 - Heat treatment

Abstract

A thermochemical method for storing and releasing thermal energy by means of a compound in solid form of formula AOxBy.zH2O, in which: A is an element selected from uranium (U) and thorium (Th); O is the element oxygen; B is an anion or an oxoanion; x is a number comprised between 0 and 4; y is a number comprised between 0 and 2; z is a number greater than 0 and less than 10; it being understood that at least one of x and y is different from 0 and that the compound of formula Th(SO4)2.xH2O is excluded.

IPC Classes  ?

• F28D 20/00 - Heat storage plants or apparatus in generalRegenerative heat-exchange apparatus not covered by groups or
• C01F 17/206 - Compounds containing only rare earth metals as the metal element oxide or hydroxide being the only anion

Abstract

The invention relates to a signal detector (10), in particular for radio-frequency signals, in particular a ?Wake Up Radio? detector, comprising: - a first circuit (20) which receives the signal as its input and is configured to set the operation point (M) at its output at a predefined DC voltage (Vm_DC) to which a variable part (?Vm) that is dependent on the signal of the input is added; and - a second circuit (30) which is connected at its input to the output of the first circuit (20) and is configured to amplify the variable part (?Vm) of the signal, this second circuit comprising a chain of at least two cascading logic inverters (32) that operate below the threshold.

IPC Classes  ?

• H04B 1/24 - Circuits for receivers in which no local oscillation is generated the receiver comprising at least one semiconductor device having three or more electrodes
• H04W 52/02 - Power saving arrangements

Abstract

The invention relates to a touch interface comprising, on the one hand, an interfacial surface able to generate a haptic-feedback effect in response to a touch of said surface by a user, and, on the other hand, at least one piezoelectric actuator configured to generate, in said interfacial surface, at least one wave of ultrasonic frequency able to endow the particles of this surface with an elliptical movement having a movement component tangential to said surface, which component is denoted ut(t), and a movement component normal to said surface, which component is denoted un(t), wherein said wave of ultrasonic frequency is chosen so that the amplitude Ut of the tangential component ut(t) and the amplitude Un of the normal component un(t) are substantially equal.

IPC Classes  ?

• G06F 3/01 - Input arrangements or combined input and output arrangements for interaction between user and computer
• G06F 3/041 - Digitisers, e.g. for touch screens or touch pads, characterised by the transducing means

Abstract

The invention relates to the identification of a new Tau species starting at residue Met11 (Met11-Tau) which is N-alpha-terminally acetylated form (N-alpha-acetyl-Met11-Tau species: Ac-Met11-Tau). Several monoclonal antibodies specific of this new Tau species have been developed. One of this antibody, 2H2/D11, was used in THY-Tau22 mouse model (that develops with age neurofibrillary degeneration (NFD) and memory deficits), and N-alpha-Ac-Met11-Tau species were clearly detected early in neurons displaying NFD on hippocampal brain sections while it is not reactive in hippocampus from elderly controls. Finally, by using ELISA sandwich specific of Ac-Met11-Tau species, Alzheimer Disease (AD) brain samples are clearly discriminated from human elderly control brains. Thus the invention relates to this new Tau species starting from the methionine residue at position 11 said methionine being N-alpha acetylated. The invention also relates to antibody that specifically binds this new tau species, a method of detection of this new Tau species and a method of diagnosis of Tauopathy disorder.

IPC Classes  ?

• C07K 14/47 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans from vertebrates from mammals
• C07K 16/18 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans
• G01N 33/68 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing involving proteins, peptides or amino acids

Abstract

Electroacoustic device (5) for generating at least one acoustic wave (Fv,Vx), the device comprising a piezoelectric substrate (10) and first (15) and second (20) groups of electrodes (60,65,70,75) arranged on the substrate, each electrode of the first and second groups comprising a track (80a-f,85a-f,90a-d,95a-d), the tracks (90a-d,95a-d) of the electrodes of the first group spiralling around a same spiral axis (Z) along a first winding direction (W1), and the tracks (80a-f,85a-f) of the electrodes of the second group spiralling around said spiral axis along a second winding direction (W2) opposite to the first winding direction.

IPC Classes  ?

• B01L 3/00 - Containers or dishes for laboratory use, e.g. laboratory glasswareDroppers
• B06B 1/02 - Processes or apparatus for generating mechanical vibrations of infrasonic, sonic or ultrasonic frequency making use of electrical energy
• B06B 1/06 - Processes or apparatus for generating mechanical vibrations of infrasonic, sonic or ultrasonic frequency making use of electrical energy operating with piezoelectric effect or with electrostriction

Abstract

Chronic obstructive pulmonary disease (COPD) remains a major cause of morbidity and mortality worldwide. Acute exacerbation of COPD (AE-COPD) in patients are mostly due to respiratory infection and are associated with an inexorable decline in lung function, enhanced oedema as well as airway and systemic inflammation. Previous results show that treatment with anti-IL-20Rb blocking antibodies increased the bacterial clearance in control mice infected by S. pneumoniae and protected CS-exposed mice from bacterial infection, by decreasing the bacterial burden and the inflammatory infiltrate. Therefore there is an interest for generating monoclonal antibodies specific for IL-20Rb with a neutralizing activity for their use in the treatment of AE-COPD. The present invention fulfills this need by providing antibodies having specificity for IL-20Rb.

IPC Classes  ?

• C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
• A61P 11/00 - Drugs for disorders of the respiratory system

Abstract

The present invention relates to the use of a starch nanoparticle loaded with at least one active molecule of interest to feed zooplankton, in particular a living prey chosen from rotifers, brine shrimp and copepods. In particular, the invention relates to the use of this loaded starch nanoparticle to increase the size and/or density and/or egg-laying rate of this zooplankton, and/or the hatching rate of the eggs thereof

IPC Classes  ?

• A61K 9/16 - AgglomeratesGranulatesMicrobeadlets
• A23K 50/80 - Feeding-stuffs specially adapted for particular animals for aquatic animals, e.g. fish, crustaceans or molluscs
• A23K 20/163 - SugarsPolysaccharides
• A23K 20/174 - Vitamins
• A61K 31/375 - Ascorbic acid, i.e. vitamin CSalts thereof
• A61K 31/714 - Cobalamins, e.g. cyanocobalamin, vitamin B12
• A61K 31/205 - Amine addition salts of organic acidsInner quaternary ammonium salts, e.g. betaine, carnitine
• A61K 33/04 - Sulfur, selenium or telluriumCompounds thereof
• A61K 31/65 - Tetracyclines
• A61K 31/198 - Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
• A61K 9/00 - Medicinal preparations characterised by special physical form
• A61P 15/08 - Drugs for genital or sexual disordersContraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis

Abstract

Agents for the treatment of patients having non-small cell lung cancer and methods of diagnostics related include an inhibitor of miR 24 3p, a locked nucleic acid, including methods of predicting response to platinum-based chemotherapy, for patients having, or suspected of having, non-small cell lung cancer.

IPC Classes  ?

• C12N 15/113 - Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides
• A61K 33/243 - PlatinumCompounds thereof
• A61P 35/00 - Antineoplastic agents
• A61P 11/00 - Drugs for disorders of the respiratory system
• C12Q 1/6886 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer

Abstract

The invention relates to a compound of formula (I) and to the pharmaceutically acceptable salts thereof. The invention also relates to the use of said compound of formula (I) in the treatment of cancer, particularly by photodynamic therapy.

IPC Classes  ?

• A61K 41/00 - Medicinal preparations obtained by treating materials with wave energy or particle radiation
• A61K 47/54 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
• A61K 49/00 - Preparations for testing in vivo
• A61P 35/00 - Antineoplastic agents

Abstract

Method comprising: supplying electricity to at least one wave transducer (25) for synthesising an ultrasonic surface wave propagating in a medium (10) to a body (15) arranged on one side of the medium, at least one portion of the electrical supply energy being converted into heat by the transducer, the electrical energy supplied to the transducer being sufficient for the heat and the energy of the ultrasonic surface wave to cause: —the body to melt when the body is in the solid state, and/or—the body to be maintained in the liquid state when the temperature of the medium is below the solidification temperature of the body.

IPC Classes  ?

• B60S 1/02 - Cleaning windscreens, windows, or optical devices
• B06B 1/06 - Processes or apparatus for generating mechanical vibrations of infrasonic, sonic or ultrasonic frequency making use of electrical energy operating with piezoelectric effect or with electrostriction
• B08B 17/02 - Preventing deposition of fouling or of dust
• B08B 7/00 - Cleaning by methods not provided for in a single other subclass or a single group in this subclass
• B08B 7/02 - Cleaning by methods not provided for in a single other subclass or a single group in this subclass by distortion, beating, or vibration of the surface to be cleaned
• G10K 11/36 - Devices for manipulating acoustic surface waves

Abstract

Aortic valve calcification is a condition in which calcium deposits form on the aortic valve in the heart. These deposits can cause narrowing at the opening of the aortic valve. This narrowing can become severe enough to reduce blood flow through the aortic valve—a condition called aortic valve stenosis. The inventors have shown that retinoic acid decreases calcification and osteoblast-like phenotype in valvular interstitial cells (VICs). More particularly, RARα activation reduces calcification and osteoblast-like phenotype in VIC. On the contrary, ALDH1A1 inhibition increases calcification and osteoblast-like phenotype in VIC. Thus the results prompt to consider that use or retinoic acid receptor (RAR) agonists would be suitable for the reversing, preventing or delaying calcification of the aortic valve.

IPC Classes  ?

• A61L 27/54 - Biologically active materials, e.g. therapeutic substances
• A61K 31/192 - Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid
• A61K 31/203 - Retinoic acids
• A61K 31/196 - Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
• A61L 27/18 - Macromolecular materials obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds

Abstract

Electroacoustic device (5) comprising: —an ultrasonic wave transducer (15) comprising a piezoelectric substrate (10) and first (30) and second (35) electrodes in contact with the piezoelectric substrate, and —a carrier (10), the transducer being attached to the carrier and acoustically coupled to the carrier, and the first and second electrodes being sandwiched, at least partly, between the piezoelectric substrate and the carrier, the device being configured to generate an ultrasonic surface wave (W) propagating through the carrier at a distance from the transducer when an electric current passes through the first and second electrodes.

IPC Classes  ?

• B06B 1/06 - Processes or apparatus for generating mechanical vibrations of infrasonic, sonic or ultrasonic frequency making use of electrical energy operating with piezoelectric effect or with electrostriction
• B08B 7/02 - Cleaning by methods not provided for in a single other subclass or a single group in this subclass by distortion, beating, or vibration of the surface to be cleaned
• B60S 1/56 - Cleaning windscreens, windows, or optical devices specially adapted for cleaning other parts or devices than front windows or windscreens

Abstract

Device for cleaning a support member covered with a liquid Electroacoustic device (10) comprising:—a support member (50),—at least two wave transducers (15a-h) which are acoustically coupled to the support member and each configured to generate an ultrasonic surface wave (Wa-h) which propagates in the support member, the propagation directions (P) of the ultrasonic surface waves generated by the transducers being different;—a control unit (40), the device comprising an analysis unit (35) which is configured to estimate the orientation of the external force (OFe) which is applied to a liquid when the liquid is in contact with the support member and/or the device being configured to receive the estimate of the orientation of the external force, the control unit being configured to control at least one of the transducers, from the estimate of the orientation of the external force, so that the acoustic force which is applied to the liquid and produced by the interaction between the ultrasonic surface wave(s) and the liquid is orientated in a predetermined direction.

IPC Classes  ?

• B60S 1/02 - Cleaning windscreens, windows, or optical devices
• B08B 7/02 - Cleaning by methods not provided for in a single other subclass or a single group in this subclass by distortion, beating, or vibration of the surface to be cleaned
• B06B 1/06 - Processes or apparatus for generating mechanical vibrations of infrasonic, sonic or ultrasonic frequency making use of electrical energy operating with piezoelectric effect or with electrostriction
• B08B 17/02 - Preventing deposition of fouling or of dust
• B60S 1/56 - Cleaning windscreens, windows, or optical devices specially adapted for cleaning other parts or devices than front windows or windscreens

Abstract

The present invention relates to a composition for promoting plants growth and/or for protecting plants against at least one plant pest and/or one plant disease, said composition comprising simultaneously at least one bacteria of the genus Bacillus producing antifungal lipopeptides, at least one fungi of the genus Trichoderma, and at least one nitrogen mineral source. The present invention also relates to the use of such a composition and to a method for obtaining such a composition. The present invention also relates to a co-culture medium for producing at least in part such a composition.

IPC Classes  ?

• A01N 63/22 - Bacillus
• A01N 63/38 - Trichoderma
• C05C 5/02 - Fertilisers containing other nitrates containing sodium or potassium nitrate
• C05F 11/08 - Organic fertilisers containing added bacterial cultures, mycelia or the like
• C05G 3/60 - Biocides or preservatives, e.g. disinfectants, pesticides or herbicidesPest repellants or attractants

Abstract

The present invention relates to the field of therapeutic treatment of polycystic ovary syndrome (PCOS). Polycystic ovary syndrome, PCOS, is the most common female reproductive disorder against which no therapeutic solution is available, beyond changes in the lifestyle. The inventors have now shown by using in vivo preclinical models, that individuals affected with PCOS have an abnormal elevated production of GnRH and that this elevated production of GnRH was transmitted to their offspring that also develop PCOS. Further, by examining AMH levels in a cohort of pregnant PCOS and control women, the inventors have found that AMH concentrations are significantly higher in PCOS women as compared to healthy women during the second trimester of gestation. These unexpected findings has allowed conceiving both prevention and treatment therapeutic strategies based on the administration of GnRH antagonists. Especially, the present invention relates to a gonadotropin-releasing hormone (GnRH) antagonist for its use in a woman affected with polycystic ovary syndrome (PCOS) for preventing the occurrence of PCOS in the offspring of the said woman. Even more interestingly, the present invention relates to a gonadotropin-releasing hormone (GnRH) antagonist for its use to rescue ovulation and fertility in postpuberal PCOS affected individuals.

IPC Classes  ?

• A61K 38/09 - Luteinising hormone-releasing hormone [LHRH]Related peptides
• A61K 31/7105 - Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
• A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca

Abstract

A Lactobacillus paracasei strain deposited at the CNCM under reference number CNCM I-5369. A mixture of the peptides having the following sequences: (SEQ ID NO 1), (SEQ ID NO 2), (SEQ ID NO 3), (SEQ ID NO 4) and (SEQ ID NO 5) and to one of the above-mentioned peptides in combination with at least one component chosen among: essential oils and particularly among essential oil of mint, essential oil of thyme, essential oil of pine tree, menthol, thymol, pinene, vitamin C, formic acid, propionic acid, citric acid, sorbic acid and lactic acid and/or a nanoparticle which may be loaded with said active ingredients.

IPC Classes  ?

• A61K 35/747 - Lactobacilli, e.g. L. acidophilus or L. brevis
• A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
• A61K 38/16 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof
• A61K 36/02 - Algae
• A61P 31/00 - Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics

Abstract

The present invention relates to the field of the diagnostic of MSI cancer. In the present work, the inventors evaluated the performance of MSISensor for the detection of MSI in dMMR/MSI mCRC from multi center, prospective patients involved in clinical trials with ICI. The present analyse demonstrated that the FDA-approved NGS-based diagnostic test for identifying MSI in mCRC and nmCRC gave inaccurate results when compared with the gold standard reference methods. Consequently, whole exome sequencing (WES) data from all samples was further analyzed to improve detection of the MSI genomic signal in CRC and other primary tumor types. This allowed them to identify the weaknesses and limits of MSISensor and then to design and validate a newly optimized algorithm, namely MSICare. The high accuracy of MSICare for the detection of MSI in CRC and non-CRC tumors should allow it to become a future reference test for assessing MSI in pan-cancer. Thus, the present invention relates to a method of diagnosing an MSI cancer in a patient in need thereof comprising notably extracting and sequencing DNA from a tumoral sample and if available from a normal sample and operate an analyse of MNRs.

IPC Classes  ?

• A61K 39/00 - Medicinal preparations containing antigens or antibodies
• C12Q 1/6886 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer

Abstract

A method to provide a microfluidic flow comprising a central flow and at least one outer flow, such that the central flow includes a first material and the at least one outer flow comprises a second material. One of the first material and the second material has cells and the other of the first material and the second material has solid particles. The method involves injection of a first suspension including the first material through a central inlet with a flow rate Q2 and injection of a second suspension comprising the second material through a pair of side inlets with a flow rate Q2, whereby the ratio of the flow rate Q2 over the flow rate Q1 is at least 4. A device provides such microfluidic flow and a method is provided to alter biological cells.

IPC Classes  ?

• C12M 3/06 - Tissue, human, animal or plant cell, or virus culture apparatus with filtration, ultrafiltration, inverse osmosis or dialysis means
• C12M 1/00 - Apparatus for enzymology or microbiology

Abstract

The present invention pertains to novel therapeutic ways for treating cognitive disorders associated with olfactory dysfunction. By using a mouse model of Down syndrome (DS—Ts65Dn mice), the present inventors have demonstrated that GnRH insufficiency is involved in the age-dependent acquisition of cognitive decline in DS and that pulsatile GnRH treatment allows reversing olfactory- and cognitive-associated impairments in DS. The present inventors have further demonstrated that GnRH insufficiency is involved in the pathological pathways of cognitive disorders in which the cognitive decline is associated with olfactory dysfunction, and, accordingly, that pulsatile GnRH administration can be used for the treatment of cognitive disorders associated with olfactory dysfunction. Accordingly, the present invention pertains to the use of GnRH for the treatment of cognitive disorders, said GnRH being administered by pulsatile administration. The present invention further pertains to a miR-200 and/or a miR-155, which are known to be involved in GnRH-secretion regulation, for use in the treatment of cognitive disorders.

IPC Classes  ?

• A61K 38/09 - Luteinising hormone-releasing hormone [LHRH]Related peptides
• A61K 31/7105 - Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
• A61P 25/28 - Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Abstract

The present invention relates to a cutaneous device (2) for the storage and release of molecules, in particular therapeutic molecules, comprising: —a support (6), —a matrix (8) configured to store and release the molecules as a function of the temperature, and —an electro-resistive layer, disposed between the support and the matrix, intended to be subjected to a voltage and comprising at least one thin microporous and/or nanoporous metal layer. The present invention also relates to a transcutaneous delivery device and the corresponding methods of manufacture and use.

IPC Classes  ?

• A61M 37/00 - Other apparatus for introducing media into the bodyPercutany, i.e. introducing medicines into the body by diffusion through the skin
• A61K 9/70 - Web, sheet or filament bases
• A61K 38/28 - Insulins

Abstract

The present disclosure relates to novel compounds of formula (I) which are useful as inhibitors of endoplasmic reticulum aminopeptidases (ERAP), in particular as inhibitors of ERAP2. The disclosure also relates to the therapeutic use of these compounds, in particular the use of these compounds in the treatment or prophylaxis of proliferative disorders, autoinflammatory disorders and autoimmune disorders.

IPC Classes  ?

• A61K 31/4192 - 1,2,3-Triazoles
• A61K 31/4439 - Non-condensed pyridinesHydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
• A61P 29/00 - Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agentsNon-steroidal antiinflammatory drugs [NSAID]
• A61P 35/00 - Antineoplastic agents
• A61P 37/00 - Drugs for immunological or allergic disorders
• C07D 409/12 - Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
• C07D 409/14 - Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings

Abstract

The present invention relates to a device for detecting a pressure, of the type comprising a detection element on which a pressure is exerted, a transducer connected to said detection element and an elastically deformable shell. Characteristically, according to the invention, said shell (1) is made of biocompatible and sterilisable material, has two opposing walls (11; 19) and an insertion opening (13), and said detection element comprises at least one elastically deformable tube (7), said tube comprises a portion arranged in said shell (1), said tube is closed at one end (71) and filled with a fluid, the other end of said tube being open, arranged outside said shell (1) and connected to said transducer (3).

IPC Classes  ?

• A61B 17/00 - Surgical instruments, devices or methods
• A61B 17/44 - Obstetrical forceps

Abstract

The invention relates to a method of treatment of Tauopathy disorder using antibody that specifically binds news Tau species, especially Tau species starting from the methionine residue at position (11), said methionine being N-alpha acetylated (AcMet11-Tau). The invention also relates to an antibody that specifically binds this new tau species. Inventors have discovered that AcMet11-Tau is a pathological Tau species that is involved in Tau pathology development. Inventors have demonstrated the causal link between AcMet11-Tau species and Tau pathology by showing that brain expression of AcMet11-Tau species potentiate Tau pathology development in Thy-Tau Transgenic mice and is involved in pathological process, at least by accelerating Tau pathology. Inventors have also used passive immunization approach based on a specific monoclonal antibody (2H2D11) in order to demonstrate that the reduction/neutralization of this Tau species in the Thy-Tau22 transgenic model of Tau pathology lead to protective effect towards Tau pathology and associated memory deficits. Furthermore, the inventors subcloned 2C12 hybridoma and selected the 2C1C8, a further antibody against N-alpha-acetyl-Met11-Tau (AcMet11-Tau). They demonstrate that the 2C1C8 antibody displayed also specificity towards N-alpha-terminally acetylated methionine11 of Tau protein and labels neurons displaying neurofibrillary degeneration in the hippocampus of Thy-Tau22 transgenic mice.

IPC Classes  ?

• C07K 16/18 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans

Abstract

A system includes sensor-actuator units fixed onto a plate to be actuated according to at least one predetermined vibratory mode, each sensor-actuator unit having an electromechanical actuator and a deformation or vibratory speed sensor, wherein the electromechanical actuator and the sensor are colocated on the surface, that is to say that the measurement by the sensor is performed in immediate proximity to the electromechanical actuator, this proximity being such that the actuator and the sensor can respectively actuate and measure the same predetermined vibratory mode.

IPC Classes  ?

• G06F 3/041 - Digitisers, e.g. for touch screens or touch pads, characterised by the transducing means
• G06F 3/01 - Input arrangements or combined input and output arrangements for interaction between user and computer
• B06B 1/02 - Processes or apparatus for generating mechanical vibrations of infrasonic, sonic or ultrasonic frequency making use of electrical energy
• B06B 1/06 - Processes or apparatus for generating mechanical vibrations of infrasonic, sonic or ultrasonic frequency making use of electrical energy operating with piezoelectric effect or with electrostriction

Abstract

The present invention relates to methods for detecting a target in a sample using mutated nanobodies, wherein an amino acid present in the loop of the FR1 region of framework of the nanobodies is mutated to cysteine.

IPC Classes  ?

• A61K 39/42 - AntibodiesImmunoglobulinsImmune serum, e.g. antilymphocytic serum viral
• A61K 39/44 - Antibodies bound to carriers
• G01N 33/569 - ImmunoassayBiospecific binding assayMaterials therefor for microorganisms, e.g. protozoa, bacteria, viruses

Abstract

The invention relates to a manufacturing method for manufacturing a positive electrode layer based on a lithiated material suitable for three-dimensional batteries or 3D batteries so as to obtain a lithiated material on a substrate, the lithiated material comprising several thin layers, i.e. layers which have thicknesses between 1 nm and 1 ?m and are made up of electrochemically active complex materials, and which are, inter alia, homogeneous and suitable for conforming to the more or less complex raised portions of the surface of the substrate on which the lithiated material is deposited.

IPC Classes  ?

• C23C 16/40 - Oxides
• C23C 16/455 - Chemical coating by decomposition of gaseous compounds, without leaving reaction products of surface material in the coating, i.e. chemical vapour deposition [CVD] processes characterised by the method of coating characterised by the method used for introducing gases into the reaction chamber or for modifying gas flows in the reaction chamber
• C23C 16/56 - After-treatment
• H01M 4/04 - Processes of manufacture in general
• H01M 4/1391 - Processes of manufacture of electrodes based on mixed oxides or hydroxides, or on mixtures of oxides or hydroxides, e.g. LiCoOx
• H01M 4/505 - Selection of substances as active materials, active masses, active liquids of inorganic oxides or hydroxides of manganese of mixed oxides or hydroxides containing manganese for inserting or intercalating light metals, e.g. LiMn2O4 or LiMn2OxFy
• H01M 4/525 - Selection of substances as active materials, active masses, active liquids of inorganic oxides or hydroxides of nickel, cobalt or iron of mixed oxides or hydroxides containing iron, cobalt or nickel for inserting or intercalating light metals, e.g. LiNiO2, LiCoO2 or LiCoOxFy

Abstract

Multi-drug resistant tuberculosis (TB) is a major public health problem concerning about half a million cases each year. Patients hardly adhere to the current strict treatment consisting of more than 10,000 tablets over a 2-year period. There is a clear need for efficient and better-formulated medications. The inventors have previously shown that nanoparticles made of cross-linked poly-#-cyclodextrins (pβCD) are efficient vehicles for pulmonary delivery of powerful combinations of anti-TB drugs. Here, they report that in addition to be efficient drug carriers, pβCD nanoparticles are endowed with intrinsic antibacterial properties. Indeed, empty pβCD are able to impair M. tuberculosis (Mtb) establishment after pulmonary administration in mice. pβCD hamper colonisation of macrophages by Mtb by interfering with lipid rafts, without inducing toxicity. Moreover, pβCD provoke macrophage apoptosis leading to depletion of infected cells, thus creating a lung micro-environment detrimental to Mtb persistence. Taken together, the results suggest that materials made of cross-linked β-cyclodextrins (e.g. nanoparticles) loaded or not with antibiotics play an antibacterial action by its own and could be used as carrier in drug regimen formulations effective against TB.20

IPC Classes  ?

• A61K 31/738 - Cross-linked polysaccharides
• A61K 31/5383 - 1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with heterocyclic ring systems
• A61K 31/4709 - Non-condensed quinolines containing further heterocyclic rings
• A61K 31/4375 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring hetero atom, e.g. quinolizines, naphthyridines, berberine, vincamine
• A61K 31/496 - Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
• A61K 31/7036 - Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin having at least one amino group directly attached to the carbocyclic ring, e.g. streptomycin, gentamycin, amikacin, validamycin, fortimicins
• A61P 31/06 - Antibacterial agents for tuberculosis

Abstract

A surface acoustic wave device includes at least one transducer; two acoustic reflectors disposed on either side of the at least one transducer so as to form a cavity, each acoustic reflector comprising an array of electrodes in the form of lines parallel with each other, each array comprising a subset of electrodes connected to a reference potential denoted mass defining a first connection type, and a subset of electrodes that are not connected to any potential, i.e. that have a floating connection defining a second connection type; at least one switching circuit configured to modify the distribution of the connections of at least one part of the electrodes of each array between the different connection types.

IPC Classes  ?

• H03H 9/145 - Driving means, e.g. electrodes, coils for networks using surface acoustic waves
• H03H 9/02 - Networks comprising electromechanical or electro-acoustic elementsElectromechanical resonators Details
• H03H 9/64 - Filters using surface acoustic waves

Abstract

A microstrip-type microwave sensor for the measurement of the dielectric properties of a solid or liquid material, constituted by a main line and two connected transmission lines integral at one of their extremities to the main line, the main line and two connected transmission lines being spaced from one another by a slot and being made integral with a substrate. The main line is connected to an electrical circuit by each of its two extremities to inject a sinusoidal signal, and wherein said main line has a width giving it an impedance in the range 50 Ohm, the two connected transmission lines being of the same width and of a length equal to one quarter of the wavelength guided in the substrate, the substrate having a height or thickness giving it flexibility or rigidity, the substrate being applied to a metallic support formed of a layer of metallic material.

IPC Classes  ?

• G01N 22/00 - Investigating or analysing materials by the use of microwaves or radio waves, i.e. electromagnetic waves with a wavelength of one millimetre or more

Abstract

Bronchial remodelling is a prominent feature of severe asthma and a potential therapeutic target. Some data indicate that Th17 cytokines in particular IL-22 may be involved in remodelling processes in vitro, and in skin remodelling in vivo. The aim of the inventors was to evaluate if Th17 cytokines are involved in bronchial remodelling in a severe model of allergic asthma, and if this was amplified by co-sensitization with NOD2 agonist, MDP, a ligand favouring Th17 polarization. Dog allergen challenge led to a predominant neutrophilic infiltration in Broncho-alveolar lavage (BAL), increased dog-specific IgE production, airways hyperresponsiveness, and increased Th17 cytokine production. Increased bronchial remodeling was observed in dog allergen challenged mice compared to control. IL-22 deficiency decreased airway hyperresponsiveness, bronchial mucus production as well as peribronchial collagen deposition, in the allergen-challenged group. Th17 cytokines in particular IL-22 participate in the bronchial remodeling in a chronic model of neutrophilic asthma, and may represent a therapeutic target in severe asthma.

IPC Classes  ?

• C07K 16/24 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
• C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
• A61K 38/17 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans
• A61P 11/06 - Antiasthmatics

Abstract

The invention relates to generation, optimization and characterisation of VHH targeted against Tau MTBD (microtubule-binding domain) with high affinity, obtained by screening from a naïve synthetic library. The inventors optimized version of a lead VHH which is able to inhibit Tau aggregation in vitro and in HEK 293 aggregation-reporting cellular model, providing a new tool in Tau immunotherapies. Accordingly the invention relates to new VHH antibody that specifically binds with high affinity Tau species, especially the epitope region involved in Tau aggregation. Moreover, the inventors found that immunization with the optimized version of this lead VHH prevented the formation of neurofibrillary tangles induced by injection of extracellular h-AD in mouse model. Thus, these specific antibodies can be used for the therapy of tauopathy disorders such as Progressive supranuclear palsy (PSP).

IPC Classes  ?

• C07K 16/18 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans
• G01N 33/68 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing involving proteins, peptides or amino acids
• A61P 25/28 - Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Abstract

1i) so as to form, at the distal end of the light guide, an illumination beam with a predefined phase function. According to the present description, said bundle (50) of single-mode optical fibers is twisted, and comprises a twist period (P) defined to preserve said phase function at the distal end of the light guide when the bundle of single-mode optical fibers is subjected to a curvature lower than said maximum curvature.

IPC Classes  ?

• G02B 23/24 - Instruments for viewing the inside of hollow bodies, e.g. fibrescopes
• A61B 1/00 - Instruments for performing medical examinations of the interior of cavities or tubes of the body by visual or photographical inspection, e.g. endoscopesIlluminating arrangements therefor
• G02B 23/26 - Instruments for viewing the inside of hollow bodies, e.g. fibrescopes using light guides

Abstract

The present invention relates novel composition to for use in a method of treating COVID-19, comprising administering to a patient a therapeutically effective amount of at least one antagonist or inhibitor of chemokine receptor CXCR4.

IPC Classes  ?

• A61K 31/395 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
• A61K 31/439 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
• A61K 31/4427 - Non-condensed pyridinesHydrogenated derivatives thereof containing further heterocyclic ring systems
• A61K 31/444 - Non-condensed pyridinesHydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. amrinone
• A61K 31/4709 - Non-condensed quinolines containing further heterocyclic rings
• A61K 31/506 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
• A61K 31/675 - Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
• A61K 38/10 - Peptides having 12 to 20 amino acids
• A61K 38/17 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans
• A61P 31/14 - Antivirals for RNA viruses
• C12Q 1/6851 - Quantitative amplification
• C12Q 1/70 - Measuring or testing processes involving enzymes, nucleic acids or microorganismsCompositions thereforProcesses of preparing such compositions involving virus or bacteriophage

Abstract

Hepatitis E virus (HEV) is annually responsible for 20 million infections with 3.4 million symptomatic cases and 70,000 deaths mainly occurring in less developed regions of the world. HEV is a non-enveloped virus containing a linear, single-stranded, positive-sense RNA genome that contains three open reading frames (ORFs), namely, ORF1, ORF2 and ORF3. ORF2 encodes the ORF2 viral capsid protein, which is involved in particle assembly, binding to host cells and eliciting neutralizing antibodies. Recently, 3 different forms of the ORF2 capsid protein were identified: infectious/intracellular ORF2 (ORF2i), glycosylated ORF2 (ORF2g), and cleaved ORF2 (ORF2c). The ORF2i protein, for which the precise sequence has been identified, is the form that is associated with infectious particles and thus antibodies having specificity for the ORF2i protein would be suitable for the diagnosis of HEV. The present fulfills this need by providing an antibody which binds to the ORF2i protein of hepatitis E virus and wherein said antibody does not bind to the ORF2g protein nor to the ORF2c of hepatitis E virus, and wherein the epitope of said antibody comprises at least one amino acid residue from amino acid residues 542 to 555 of SEQ ID NO: 1.

IPC Classes  ?

• C07K 16/10 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
• G01N 33/576 - ImmunoassayBiospecific binding assayMaterials therefor for hepatitis
• G01N 33/535 - Production of labelled immunochemicals with enzyme label

Abstract

The present disclosure relates to modified forms, or muteins, of IL-10, as well as variants thereof, which display improved features as compared to wild-type IL-10. The present invention further relates to the use of such modified forms, or muteins, of IL-10, as well as variants thereof in methods, including therapeutic methods.

IPC Classes  ?

• C07K 14/52 - CytokinesLymphokinesInterferons

Abstract

Hepatitis E virus (HEV) is annually responsible for 20 million infections with 3.4 million symptomatic cases and 70,000 deaths mainly occurring in less developed regions of the world. HEV is a quasi-enveloped virus containing a linear, single-stranded, positive-sense RNA genome that contains three open reading frames (ORFs), namely, ORF1, ORF2 and ORF3. ORF2 encodes the ORF2 viral capsid protein, which is involved in particle assembly, binding to host cells and eliciting neutralizing antibodies. Recently, 3 different forms of the ORF2 capsid protein were identified: infectious/intracellular ORF2 (ORF2i), glycosylated ORF2 (ORF2g), and cleaved ORF2 (ORF2c). The ORF2i protein, for which the precise sequence has been identified, is the form that is associated with infectious particles and thus antibodies having specificity for the ORF2i protein would be suitable for the diagnosis of HEV. The present fulfills this need by providing an antibody which binds to the ORF2i protein of hepatitis E virus and wherein said antibody does not bind to the ORF2g protein nor to the ORF2c of hepatitis E virus, and wherein the epitope of said antibody comprises at least one amino acid residue from amino acid residues 10 to 23 of SEQ ID NO: 1.

IPC Classes  ?

• C07K 16/10 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
• G01N 33/576 - ImmunoassayBiospecific binding assayMaterials therefor for hepatitis
• G01N 33/558 - ImmunoassayBiospecific binding assayMaterials therefor using diffusion or migration of antigen or antibody

Abstract

An optical fibre, for use in the field of distributed measurement of temperature or deformation by optical reflectometry in the frequency domain using the Rayleigh backscattered signal in the fibre, includes a core doped with nanoparticles for example formed from gold particles covered with zirconium oxide, and can be subjected to high temperatures during the measurement. A method for producing the optical fibre includes a step of heat treatment during which the optical fibre is subjected, for a duration of at least one hour, to a heat treatment temperature higher than a maximum temperature to which it will be subjected during a measurement.

IPC Classes  ?

• G01K 11/32 - Measuring temperature based on physical or chemical changes not covered by group , , , or using changes in transmittance, scattering or luminescence in optical fibres
• C03B 37/014 - Manufacture of preforms for drawing fibres or filaments made entirely or partially by chemical means
• C03B 37/027 - Fibres composed of different sorts of glass, e.g. fibre optics
• G01B 11/16 - Measuring arrangements characterised by the use of optical techniques for measuring the deformation in a solid, e.g. optical strain gauge
• G02B 6/02 - Optical fibres with cladding

Abstract

The present invention relates to a method for predicting neurodegenerative decline and/or its severity for a patient, especially of cognitive impairment (CI). Strokes and Parkinson's disease are frequently associated with occurrence of long-term cognitive impairment or dementia with still incompletely resolved mechanisms. The discovery of diagnostic and predictive biomarkers thus remains a major challenge. The method of the invention uses radiomics corresponding to texture features extracted from a plurality of previously-acquired medical brain images and correlated with previously-acquired clinical and/or biological data. A classifier is trained beforehand for learning these radiomics, and then operated on radiomics computed from at least one brain image of a patient to generate a score representative of its risks of neurodegenerative decline. By applying this method on a cohort of 160 MCI and non-MCI patients, the inventors show that MCI patients could be early predicted with a mean accuracy of 88%. In the same way, the method was able to discriminate very early stages of cognitive decline in a Parkinson's disease population of 100 patients.

IPC Classes  ?

• A61B 5/00 - Measuring for diagnostic purposes Identification of persons
• A61B 5/055 - Detecting, measuring or recording for diagnosis by means of electric currents or magnetic fieldsMeasuring using microwaves or radio waves involving electronic [EMR] or nuclear [NMR] magnetic resonance, e.g. magnetic resonance imaging
• G06T 7/00 - Image analysis
• G06T 7/10 - SegmentationEdge detection
• G06T 7/40 - Analysis of texture
• G16H 30/40 - ICT specially adapted for the handling or processing of medical images for processing medical images, e.g. editing
• G16H 50/20 - ICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for computer-aided diagnosis, e.g. based on medical expert systems
• G16H 50/30 - ICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for calculating health indicesICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for individual health risk assessment

Abstract

A nanostructure transfer method is provided. The method includes providing a first substrate (10) having thereon a plurality of nanostructures (12), the nanostructures (12) extending away from the first substrate (10). A solder material (14) is deposited on distal ends of the nanostructures (12). A second substrate (18) having thereon a first metal layer (20) is provided. The solder material (14) is bonded to the first metal layer (20), thereby attaching the nanostructures (12) to the second substrate (18). The attached nanostructures (12) are then released from the first substrate (10).

IPC Classes  ?

• B81C 1/00 - Manufacture or treatment of devices or systems in or on a substrate
• H01L 51/00 - Solid state devices using organic materials as the active part, or using a combination of organic materials with other materials as the active part; Processes or apparatus specially adapted for the manufacture or treatment of such devices, or of parts thereof

Abstract

out.

IPC Classes  ?

• G06N 3/065 - Analogue means
• G06N 3/044 - Recurrent networks, e.g. Hopfield networks
• G06N 3/049 - Temporal neural networks, e.g. delay elements, oscillating neurons or pulsed inputs
• G06N 3/06 - Physical realisation, i.e. hardware implementation of neural networks, neurons or parts of neurons
• G11C 11/41 - Digital stores characterised by the use of particular electric or magnetic storage elementsStorage elements therefor using electric elements using semiconductor devices using transistors forming cells with positive feedback, i.e. cells not needing refreshing or charge regeneration, e.g. bistable multivibrator or Schmitt trigger
• G11C 11/54 - Digital stores characterised by the use of particular electric or magnetic storage elementsStorage elements therefor using elements simulating biological cells, e.g. neuron

Abstract

A process for detecting the sensitivity of one or more polymers and/or of one or more, mixtures of polymers to a compound, including the steps of exposing at least one lens-shaped micro-deposit, including the polymer(s) and/or the mixture(s) of polymers, to the compound, and detecting, by illuminating the surface of this micro-deposit, a change in the spatial distribution of the intensity of the light reflected or transmitted by this micro-deposit, linked to a variation in the dimensions and/or refractive index of this micro-deposit, under the effect of an interaction between the polymer(s) and/or the mixture(s) of polymers and the compound.

IPC Classes  ?

• G01N 21/41 - RefractivityPhase-affecting properties, e.g. optical path length
• G01N 21/47 - Scattering, i.e. diffuse reflection
• G01N 21/45 - RefractivityPhase-affecting properties, e.g. optical path length using interferometric methodsRefractivityPhase-affecting properties, e.g. optical path length using Schlieren methods
• C12Q 1/34 - Measuring or testing processes involving enzymes, nucleic acids or microorganismsCompositions thereforProcesses of preparing such compositions involving hydrolase
• G01N 21/55 - Specular reflectivity
• G01N 21/77 - Systems in which material is subjected to a chemical reaction, the progress or the result of the reaction being investigated by observing the effect on a chemical indicator

Abstract

The disclosure relates to an antibody which is directed against galectin-9 and is an inhibitor of the suppressor activity of regulatory T lymphocytes, and also to the use of this antibody for the treatment of diseases associated with the suppressor activity of regulatory T lymphocytes, in particular the treatment of cancer.

IPC Classes  ?

• C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
• C07K 16/30 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
• C07K 16/18 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans
• A61K 39/395 - AntibodiesImmunoglobulinsImmune serum, e.g. antilymphocytic serum
• A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca

Abstract

The invention relates to a dynamic method for determining the formation of a Winsor III microemulsion system, the method comprising the steps of: providing a mixture of an aqueous medium and a hydrocarbon medium in a chamber; continuously altering the concentration of at least one component in the mixture, while the ratio of the aqueous medium to the hydrocarbon medium remains constant and while stirring the mixture; and continuously measuring at least one physicochemical property of the mixture. The invention further relates to a device for determining the formation of a Winsor III microemulsion system.

IPC Classes  ?

• C09K 8/584 - Compositions for enhanced recovery methods for obtaining hydrocarbons, i.e. for improving the mobility of the oil, e.g. displacing fluids characterised by the use of specific surfactants
• G01N 21/51 - Scattering, i.e. diffuse reflection within a body or fluid inside a container, e.g. in an ampoule

Abstract

A phonon parametric oscillator is provided. The phonon parametric oscillator comprises a laser for periodically emitting brief optical pulses (IL), an assembly for generating acoustic pulses (IA) and a medium for coupling the acoustic pulses to an object (O), the assembly for generating acoustic pulses comprising an entrance face, an exit face, a conversion medium for converting the brief optical pulses into acoustic pulses and a propagation medium for propagating said acoustic pulses, the entrance and exit faces being reflective to the acoustic pulses, the propagation medium having a defined thickness, the exit face making contact with the coupling medium. In the phonon parametric oscillator according to the invention, the round-trip time of an acoustic pulse due to reflection from the entrance and exit faces, is equal to the emission period (τ) of the laser, so that the reflected acoustic pulse is in phase with the following acoustic pulse.

IPC Classes  ?

• G10K 15/04 - Sound-producing devices

Abstract

The present invention relates to compounds of formula (I), their enantiomers and their pharmaceutically acceptable salts, and their use in therapy, particularly for the treatment of cancer or inflammatory diseases.

IPC Classes  ?

• C07D 207/16 - Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
• A61K 31/4015 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having oxo groups directly attached to the heterocyclic ring, e.g. piracetam, ethosuximide
• A61K 31/4025 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
• A61K 31/4439 - Non-condensed pyridinesHydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
• A61K 39/395 - AntibodiesImmunoglobulinsImmune serum, e.g. antilymphocytic serum
• A61P 1/00 - Drugs for disorders of the alimentary tract or the digestive system
• A61P 35/00 - Antineoplastic agents
• C07D 401/12 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
• C07D 409/12 - Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links

Abstract

The present invention relates to the treatment of microbiome dysregulations. Said dysregulations may subsequently contribute to the development of several chronic diseases. Thus characterization of new post-biotic compounds inducing beneficial changes on host-microbiota interactions may be highly desirable. The inventors showed that Nlrp6 diurnally coordinates cyclical adaptation of the gut microbiota diversity to epithelial plasticity in response to a treatment with a Csnk2 inhibitor. The invention therefore relates to an inhibitor of Csnk2, for use in the treatment of microbiome dysregulations notably associated with circadian clock disruption. Said inhibitor may be selected among chemically synthesized or natural selective Csnk2 inhibitors such as flavones.

IPC Classes  ?

• A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
• C07D 487/04 - Ortho-condensed systems
• A61K 31/4985 - Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
• A61K 31/5377 - 1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
• A61K 31/353 - 3,4-Dihydrobenzopyrans, e.g. chroman, catechin
• A61P 1/00 - Drugs for disorders of the alimentary tract or the digestive system
• A61K 31/277 - NitrilesIsonitriles having a ring, e.g. verapamil

Abstract

The present invention relates to the Lactobacillus paracasei strain deposited at the CNCM under reference number CNCM I-5369 The present invention also relates to a mixture of the peptides having the following sequences: (SEQ ID NO 1), (SEQ ID NO 2), (SEQ ID NO 3), (SEQ ID NO 4) and (SEQ ID NO 5) and to one of the above-mentioned peptides in combination with at least one component chosen among: - essential oils and particularly among essential oil of mint, essential oil of thyme, essential oil of pine tree, menthol, thymol, pinene, - vitamin C, formic acid, propionic acid, citric acid, sorbic acid and lactic acid and/or - a nanoparticle which may be loaded with said active ingredients.

IPC Classes  ?

• A61K 35/747 - Lactobacilli, e.g. L. acidophilus or L. brevis
• A61K 38/16 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof
• C07K 14/335 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from bacteria from Lactobacillus (G)
• C12N 1/20 - BacteriaCulture media therefor

Abstract

An optical sensor, especially an artificial retina, that includes at least one photosensitive cell. Each cell includes a integration capacitor, a read circuit the operation of which depends on the charge of the integration capacitor, at least one MOS transistor operating subthreshold, and the drain-source current of which influences the charge on the integration capacitor, and at least one photodiode operating in photovoltaic mode and connected to the gate of this transistor, such that the drain-source current of the MOS transistor depends on the optical power received by the photodiode.

IPC Classes  ?

• A61N 1/05 - Electrodes for implantation or insertion into the body, e.g. heart electrode
• A61N 1/36 - Applying electric currents by contact electrodes alternating or intermittent currents for stimulation, e.g. heart pace-makers
• G01J 1/46 - Electric circuits using a capacitor
• G06N 3/04 - Architecture, e.g. interconnection topology
• H04N 5/3745 - Addressed sensors, e.g. MOS or CMOS sensors having additional components embedded within a pixel or connected to a group of pixels within a sensor matrix, e.g. memories, A/D converters, pixel amplifiers, shared circuits or shared components
• H04N 5/378 - Readout circuits, e.g. correlated double sampling [CDS] circuits, output amplifiers or A/D converters
• G01J 1/44 - Electric circuits

Abstract

Electroacoustic device that includes a body, an electrode to be electrically powered, named hot electrode, and an electrode to be electrically grounded, named ground electrode. The body includes a piezoelectric part or the electroacoustic device further including a piezoelectric part different from the body. The hot electrode includes a hot track spiraling around a spiral axis. The radial step between two consecutive coils of the hot track decreasing radially from the spiral axis. The hot electrode and the ground electrode are arranged on the piezoelectric part such as to define a wave transducer configured to generate a focalised ultrasonic vortex propagating in the body and/or, when a fluid medium is acoustically coupled with the electroacoustic device, in the fluid medium.

IPC Classes  ?

• B06B 1/06 - Processes or apparatus for generating mechanical vibrations of infrasonic, sonic or ultrasonic frequency making use of electrical energy operating with piezoelectric effect or with electrostriction
• B06B 3/04 - Processes or apparatus specially adapted for transmitting mechanical vibrations of infrasonic, sonic or ultrasonic frequency involving focusing or reflecting
• B01L 3/00 - Containers or dishes for laboratory use, e.g. laboratory glasswareDroppers
• B01L 99/00 - Subject matter not provided for in other groups of this subclass

Abstract

The invention relates to a composite material based on boron nitride (BN(C)) in the form of a continuous structure; and a phase change material (PCM) incorporated within said continuous BN(C) structure and is embedded within a polymer layer, a process for manufacturing same, and the components that comprise same.

IPC Classes  ?

• C04B 35/583 - Shaped ceramic products characterised by their compositionCeramic compositionsProcessing powders of inorganic compounds preparatory to the manufacturing of ceramic products based on non-oxides based on borides, nitrides or silicides based on boron nitride
• C04B 38/00 - Porous mortars, concrete, artificial stone or ceramic warePreparation thereof
• C04B 41/45 - Coating or impregnating
• C04B 41/53 - After-treatment of mortars, concrete, artificial stone or ceramicsTreatment of natural stone involving the removal of part of the materials of the treated article
• C04B 41/82 - Coating or impregnating with organic materials
• C04B 41/85 - Coating or impregnating with inorganic materials
• F28D 20/02 - Heat storage plants or apparatus in generalRegenerative heat-exchange apparatus not covered by groups or using latent heat
• H01L 23/427 - Cooling by change of state, e.g. use of heat pipes

Abstract

Disclosed is a microemulsion of oil-in-water type including, preferably consisting of, by weight relative to the total weight of microemulsion: •70% to 94% of water, •1% to 15% of at least one hydrophobic fragrancing substance, •4% to 20% of at least one preferably volatile solvo-surfactant, and •0.1% to 15%, preferably 1% to 13%, of at least one hydrotropic agent or at least one surfactant selected from anionic surfactants, cationic surfactants, amphoteric surfactants and non-ionic surfactants. The solvo-surfactant is selected from monoalkylated glycerol derivatives of following formula (I): wherein the “alkyl” group is a linear or branched alkyl group including from 1 to 8 carbon atoms, and R and R′ are each independently H or a linear or branched alkyl group including from 1 to 5 carbon atoms, with the proviso that R is different from R′, and mixtures thereof.

IPC Classes  ?

• A61Q 13/00 - Formulations or additives for perfume preparations
• A61K 8/06 - Emulsions
• A61K 8/33 - Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
• A61K 8/34 - Alcohols
• A61K 8/35 - Ketones, e.g. quinones, benzophenone
• A61K 8/37 - Esters of carboxylic acids
• A61K 8/44 - Aminocarboxylic acids or derivatives thereof, e.g. aminocarboxylic acids containing sulfurSalts, esters or N-acylated derivatives thereof
• A61K 8/46 - Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing sulfur
• A61K 8/49 - Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
• A61K 8/60 - SugarsDerivatives thereof

Abstract

A device for measuring an acceleration includes a vibrating accelerometer including: a semiconductor substrate forming a fixed frame of the accelerometer; a test weight of the same material as the substrate and connected to the fixed frame, movable translationally along at least one sensing axis of the vibrating accelerometer; a guide of the same material as the substrate, connected to the fixed frame and test weight, guiding the test weight in the direction of the sensing axis; a layer made of a piezoelectric semiconductor deposited on the substrate, the layer being tensilely prestrained; a resonator in the layer connected to the fixed frame, the resonator subjected to tension or compression in the direction of the sensing axis; and at least one transducer connected to the resonator, able to actuate the resonator, to keep the resonator oscillating and/or to detect an electrical signal generated by the resonator.

IPC Classes  ?

• G01P 15/09 - Measuring accelerationMeasuring decelerationMeasuring shock, i.e. sudden change of acceleration by making use of inertia forces with conversion into electric or magnetic values by piezoelectric pick-up
• G01P 15/097 - Measuring accelerationMeasuring decelerationMeasuring shock, i.e. sudden change of acceleration by making use of inertia forces with conversion into electric or magnetic values by vibratory elements
• G01P 1/00 - Details of instruments

Abstract

1), at least one of said inclusions being actively doped.

IPC Classes  ?

• H01S 3/067 - Fibre lasers
• H01S 3/16 - Solid materials
• G02B 6/02 - Optical fibres with cladding

Abstract

System (1) for treatment by photodynamic therapy comprising an illuminating member (6) which comprises: —a core (35) carrying a light emitting surface (37), and —a hollow sheath (10) adapted to receive the core (35) with the light emitting surface (37) arranged within a balloon (11), the balloon (11) comprising a wall (12) which has an inner surface delimiting an internal space, and an outer surface, the wall (12) being flexible, wherein the internal space of the balloon (11) has a variable capacity, the wall (12) of the balloon (11) being elastically extendible and the balloon (11) presenting a plurality of inflated states in each of which the internal space is filled with a volume of light diffusing solution, and wherein the system further comprises a support provided with a transfer function relating the volume of light diffusing solution of each inflated state with at least one of a corresponding distribution of light power at the outer surface of the wall (12) of the balloon (11) and a corresponding time of illumination for providing a determined dose of light energy.

IPC Classes  ?

• A61N 5/06 - Radiation therapy using light
• A61N 5/067 - Radiation therapy using light using laser light

Abstract

2O) with a solid reagent and at least one oxidizing system with an agent for oxidizing the solid reagent present in the reduced state, wherein the system of oxidizing the hydrogen sulfide to sulfur and the system for oxidizing the solid reagent, are so arranged that the hydrogen sulfide is not brought into contact with the agent oxidizing the solid reagent.

IPC Classes  ?

• C01B 17/04 - Preparation of sulfurPurification from gaseous sulfur compounds including gaseous sulfides
• B01J 4/00 - Feed devicesFeed or outlet control devices
• B01J 8/24 - Chemical or physical processes in general, conducted in the presence of fluids and solid particlesApparatus for such processes with fluidised particles according to "fluidised-bed" technique
• B01J 23/22 - Vanadium
• B01J 38/12 - Treating with free oxygen-containing gas

Abstract

A process for detecting the sensitivity of one or more polymers and/or of one or more mixtures of polymers to a compound, including the steps of exposing a plurality of individualized micro-deposits including the polymer(s) and/or the mixture(s) of polymers to the compound, and detecting, by interferometry, a variation in appearance of an assembly of micro-deposits exposed to the compound and/or a variation in the dimensions and/or refractive index of at least one of the micro-deposits exposed to the compound, linked to an interaction between the polymer(s) and/or the mixture(s) of polymers and the compound.

IPC Classes  ?

• G01N 21/45 - RefractivityPhase-affecting properties, e.g. optical path length using interferometric methodsRefractivityPhase-affecting properties, e.g. optical path length using Schlieren methods
• G01N 21/77 - Systems in which material is subjected to a chemical reaction, the progress or the result of the reaction being investigated by observing the effect on a chemical indicator
• G01N 21/17 - Systems in which incident light is modified in accordance with the properties of the material investigated

Abstract

Disclosed is a functionalizing method for the end functionalisation of trans-1,4 stereo-regular polydiene chains obtained by the coordination catalytic polymerisation of at least one conjugated diene monomer. It also relates to a polydiene having a trans-1,4 chain formation rate of at least 85%, preferably at least 90%, and an end functionalisation rate higher than 70%, preferably higher than 80%, and more preferably higher than 90%.

IPC Classes  ?

• C08F 36/14 - Homopolymers or copolymers of compounds having one or more unsaturated aliphatic radicals, at least one having two or more carbon-to-carbon double bonds the radical having only two carbon-to-carbon double bonds conjugated containing elements other than carbon and hydrogen
• C08F 4/54 - MetalsMetal hydridesMetallo-organic compoundsUse thereof as catalyst precursors selected from light metals, zinc, cadmium, mercury, copper, silver, gold, boron, gallium, indium, thallium, rare earths, or actinides together with other compounds thereof
• C08F 36/08 - Isoprene
• C08F 36/06 - Butadiene
• C08F 36/04 - Homopolymers or copolymers of compounds having one or more unsaturated aliphatic radicals, at least one having two or more carbon-to-carbon double bonds the radical having only two carbon-to-carbon double bonds conjugated
• C08K 5/56 - Organo-metallic compounds, i.e. organic compounds containing a metal-to-carbon bond